Aclaris Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
11.61 |
5.77 |
5.47 |
6.58 |
11.73 |
43.08 |
| Przychód Δ r/r |
0.00% |
-50.31% |
-5.10% |
20.27% |
78.16% |
267.26% |
| Przychód (min) |
10.06 |
1.35 |
0.50 |
1.62 |
2.88 |
10.58 |
| Przychód (max) |
13.76 |
10.46 |
24.65 |
18.26 |
32.52 |
119.45 |
| EBITDA (średnia) |
-11.61 |
-5.77 |
-5.47 |
-6.58 |
-11.73 |
-43.08 |
| EBIT (średnia) |
-11.61 |
-5.77 |
-5.47 |
-6.58 |
-11.73 |
-43.08 |
| EBIT % |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
| Zysk netto (średni) |
-65.70 |
-42.07 |
-43.23 |
-48.47 |
-58.20 |
-58.55 |
| Zysk netto % |
-565.95% |
-729.33% |
-789.62% |
-736.13% |
-496.15% |
-135.92% |
| EPS (średnia) |
-0.82 |
-0.54 |
-0.60 |
-0.65 |
-0.75 |
-0.76 |
| Liczba analityków (Przychody) |
5 |
5 |
8 |
6 |
2 |
5 |
| Liczba analityków (EPS) |
5 |
6 |
6 |
6 |
3 |
4 |
| symbol |
ACRS |
ACRS |
ACRS |
ACRS |
ACRS |
ACRS |